Delivery Order SPE2DB20D3103-SPE2DB25FP5R7
- Not listed
- The Defense Logistics Agency awarded a $41,453.26 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $3,877.08 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen medications on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a $10,734.58 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 21, 2025, with performance undertaken at the contractor's corporate office in Conshohocken, Pennsylvania. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp fulfills this delivery order under its larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $15,470.70 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical products...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml pens. The contract has a ceiling value of $110,301.03 and is a firm fixed price, non-set-aside delivery order with a performance period ending on May 1, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,006.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen auto-injectors. The contract, executed on July 18, 2025, with an ultimate completion date of July 21, 2025, operates under firm fixed-price terms with no set-aside designation. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $12,507.37 to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. This order is for the supply of the specialty pharmaceutical product Dupixent 300 mg/2 ml pen, with an ultimate completion date of March 19, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $27,323.19 under firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of July 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. This delivery order is issued under AmerisourceBergen's...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP5R7Delivery Order
The Defense Logistics Agency awarded a $15,942.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, supplying a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies through its relationship with the Defense Logistics Agency. The SPE2DX prime vendor contract establishes AmerisourceBergen as a key supplier to support Defense Health Agency operations and other government healthcare systems globally. This delivery order for Dupixent, a biologic medication used to treat conditions such as atopic dermatitis and eosinophilic asthma, reflects the company's role in providing specialized pharmaceutical commodities to support military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.9k | 7/18/25 |